Arbios adds University of California at San Francisco as clinical site for trial of Sepet Liver Assist Device

By Lisa Kerner

Charlotte, N.C., July 6 - Arbios Systems, Inc. said the University of California at San Francisco Medical Center will serve as an additional clinical site in the ongoing clinical trial for the company's Sepet Liver Assist Device.

Patient enrollment at the site is expected to begin shortly. Other clinical sites include the Albert Einstein Medical Center in Philadelphia, Cedars Sinai Medical Center in Los Angeles, and the University of California at San Diego.

Arbios' device is a sterile, disposable cartridge containing microporous hollow fibers that help remove harmful toxins and impurities from the blood.

"UCSF treats and transplants exceptional numbers of patients with liver failure, and their participation should facilitate successful completion of this important trial," president and chief executive officer Walter Ogier said in a company news release.

The objectives of the trial are to assess the safety and tolerability of Sepet, as well as its preliminary effectiveness in reversing liver failure and resultant encephalopathy in up to 20 patients.

Arbios is a medical device and cell-based therapy company based in Waltham, Mass.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.